TCA
APTO

Transcend Capital Advisors’s Aptose Biosciences, Inc. APTO Stock Holding History

Transcend Capital Advisors’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-53
Closed -$15.4K – 520
2023
Q1 		$15.4K Hold
53
– – ﹤0.01% 476
2022
Q4 		$13.9K Hold
53
– – ﹤0.01% 487
2022
Q3 		$14K Hold
53
– – ﹤0.01% 479
2022
Q2 		$18K Hold
53
– – ﹤0.01% 494
2022
Q1 		$33K Hold
53
– – ﹤0.01% 508
2021
Q4 		$32K Hold
53
– – ﹤0.01% 481
2021
Q3 		$50K Hold
53
– – ﹤0.01% 483
2021
Q2 		$80K Hold
53
– – 0.01% 320
2021
Q1 		$144K Buy
+53
New +$105K 0.02% 399

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
AC
Annandale Capital Dallas, Texas $709M AUM 11.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Transcend Capital Advisors's APTO Position: Q2 2023 in Review

Transcend Capital Advisors sold out of Aptose Biosciences, Inc. (APTO) in Q2 2023, closing a stake of 53 shares — an estimated $15.4K sold.

Transcend Capital Advisors first reported a position in APTO in Q1 2021 and held it in 9 quarters. The position peaked at $144K in Q1 2021. 24 funds tracked by Wall St. Rank hold APTO as of Q2 2023.

  • Transcend Capital Advisors reported no remaining Aptose Biosciences, Inc. position as of Q2 2023 after selling out during the quarter.
  • Transcend Capital Advisors sold 53 Aptose Biosciences, Inc. shares in Q2 2023, an estimated $15.4K.
  • Transcend Capital Advisors first reported a position in Aptose Biosciences, Inc. in Q1 2021 and held it in 9 quarters.
  • Transcend Capital Advisors's Aptose Biosciences, Inc. position peaked at $144K in Q1 2021.
  • 24 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2023.

Based on Transcend Capital Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.